The G3 Domain of Versican Inhibits Mesenchymal Chondrogenesis Via the Epidermal Growth Factor-like Motifs
Yaou Zhang,Liu Cao,Chris Gholam Kiani,Bing L. Yang,Burton B. Yang
DOI: https://doi.org/10.1074/jbc.273.49.33054
IF: 5.485
1998-01-01
Journal of Biological Chemistry
Abstract:Versican is a highly expressed proteoglycan in zones of developing tissues. To investigate whether versican plays a role in cell differentiation, we studied its role in mesenchymal condensation and chondrogenesis. Here we report that a mini-versican gene product inhibits mesenchymal chondrogenesis but not condensation. The mini-versican-treated mesenchymal cultures form fewer, smaller cartilaginous nodules and produced lower levels of link protein and type II collagen. The versican G3 domain alone, but not G1, was sufficient to inhibit mesenchymal chondrogenesis. Deletion of two epidermal growth factor (EGF)-like motifs in the G3 domain abolished the effect of versican. The G3 domain of aggrecan, which does not contain an EGF-like motif, did not inhibit mesenchymal chondrogenesis. We also generated a chimera construct containing the two EGF-like motifs of versican and the G3 domain of aggrecan, and we observed that this chimera construct inhibited chondrogenesis to a lesser extent than did the full-length versican G3 construct. Direct transfection of mesenchymal cells with different constructs produced similar results. Furthermore, treatment with versican antisense oligonucleotides and transfection with a versican antisense construct promoted chondrogenesis. Taken together, our results strongly suggest that versican inhibits mesenchymal chondrogenesis via its EGF-like motifs. Versican is a highly expressed proteoglycan in zones of developing tissues. To investigate whether versican plays a role in cell differentiation, we studied its role in mesenchymal condensation and chondrogenesis. Here we report that a mini-versican gene product inhibits mesenchymal chondrogenesis but not condensation. The mini-versican-treated mesenchymal cultures form fewer, smaller cartilaginous nodules and produced lower levels of link protein and type II collagen. The versican G3 domain alone, but not G1, was sufficient to inhibit mesenchymal chondrogenesis. Deletion of two epidermal growth factor (EGF)-like motifs in the G3 domain abolished the effect of versican. The G3 domain of aggrecan, which does not contain an EGF-like motif, did not inhibit mesenchymal chondrogenesis. We also generated a chimera construct containing the two EGF-like motifs of versican and the G3 domain of aggrecan, and we observed that this chimera construct inhibited chondrogenesis to a lesser extent than did the full-length versican G3 construct. Direct transfection of mesenchymal cells with different constructs produced similar results. Furthermore, treatment with versican antisense oligonucleotides and transfection with a versican antisense construct promoted chondrogenesis. Taken together, our results strongly suggest that versican inhibits mesenchymal chondrogenesis via its EGF-like motifs. epidermal growth factor reverse transcriptase polymerase chain reaction Dulbecco's modified Eagle's medium polyacrylamide gel electrophoresis nitrilotriacetic acid peanut agglutinin. Versican is expressed in a variety of tissues. High concentrations are found in embryonic tissues, such as human embryonic lung (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar), the mesenchymal cell condensation area of limb buds (2Kimata K. Oike Y. Tani K. Shinomura T. Yamagata M. Uritani M. Suzuki S. J. Biol. Chem. 1986; 261: 13517-13525Abstract Full Text PDF PubMed Google Scholar, 3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar), the perinotochordal mesenchyme between the notochord and neural tube, and basement membranes facing the neuroepithelial cells of chicks (4Yamagata M. Shinomura T. Kimata K. Anat. Embryol. 1993; 187: 433-444Crossref PubMed Scopus (82) Google Scholar). It is also present in embryonic aorta, lung, cornea, and skeletal muscle (4Yamagata M. Shinomura T. Kimata K. Anat. Embryol. 1993; 187: 433-444Crossref PubMed Scopus (82) Google Scholar). In adult tissues, versican is detected in the loose connective tissue of various organs including most smooth muscles, the central and peripheral nervous systems, the luminal surface of glandular epithelia (5Bode-Lesniewska B. Dours-Zimmermann M.T. Odermattm B.F. Briner J. Heitz P.U. Zimmermann D.R. J. Histochem. Cytochem. 1996; 44: 303-312Crossref PubMed Scopus (162) Google Scholar), blood vessels (6Yao L.Y. Moody C. Schonherr E. Wight T.N. Sandell L.J. Matrix Biol. 1994; 14: 213-225Crossref PubMed Scopus (104) Google Scholar), vessels of brain tumors (7Paulus W. Baur I. Dours-Zimmermann M.T. Zimmerman D.R. J. Neuropath. Exp. Neurol. 1996; 55: 528-533Crossref PubMed Scopus (94) Google Scholar), dermis, and in the proliferative zone of the epidermis (8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar).Versican (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 9Shinomura T. Nishida Y. Ito K. Kimata K. J. Biol. Chem. 1993; 268: 14461-14469Abstract Full Text PDF PubMed Google Scholar) is a member of the large aggregating chondroitin sulfate proteoglycan family (10Margolis R.U. Margolis R.K. Methods Enzymol. 1994; 245: 105-126Crossref PubMed Scopus (88) Google Scholar), which also includes aggrecan, neurocan, and brevican. All contain G1 domains at their amino termini and G3 domains at their carboxyl termini. A varying number of chondroitin sulfate side chains are attached to a central chondroitin sulfate bearing sequence; in versican, 12–15 chondroitin sulfate side chains are covalently attached to this sequence (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 11Krusius T. Gehlsen K.R. Ruoslahti E. J. Biol. Chem. 1987; 262: 13120-13125Abstract Full Text PDF PubMed Google Scholar). This central sequence contains two alternatively spliced domains, glycosaminoglycan-α and glycosaminoglycan-β (12Dours-Zimmermann M.T. Zimmermann D.R. J. Biol. Chem. 1994; 269: 32992-32998Abstract Full Text PDF PubMed Google Scholar, 13Naso M.F. Zimmermann D.R. Iozzo R.V. J. Biol. Chem. 1994; 269: 32999-33008Abstract Full Text PDF PubMed Google Scholar, 14Naso M.F. Morgan J.L. Buchberg A.M. Siracusa L.D. Iozzo R.V. Genomics. 1995; 29: 297-300Crossref PubMed Scopus (29) Google Scholar).The functions of these proteoglycans remain elusive. Different domains may be involved in different cellular processes. The G1 domain of versican, as well as that of other members of that family, binds hyaluronan and may participate in matrix assembly and cell-cell and cell-matrix interactions. The G3 domain, consisting of lectin-like (also called carbohydrate regulatory domain), epidermal growth factor-like (EGF1-like), and complement binding protein motifs, is structurally similar to the selectin family (15Springer T.A. Lasky L.A. Nature. 1991; 349: 196-197Crossref PubMed Scopus (411) Google Scholar). But whereas selectins play a role in mediating cell adhesion, no such function has been identified for the G3 domain of versican. It is possible that the EGF-like and lectin-like motifs are involved in intercellular signaling or cell recognition processes. The chondroitin sulfate chains of versican are reported to inhibit cell adhesion (16Yamagata M. Suzuki S. Akiyama S.K. Yamada K.M. Kimata K. J. Biol. Chem. 1989; 264: 8012-8018Abstract Full Text PDF PubMed Google Scholar, 17Yamagata M. Saga S. Kato M. Bernfield M. Kimata K. J. Cell Sci. 1993; 106: 55-65Crossref PubMed Google Scholar).Thus, versican is suspected to play a role in cellular attachment, migration, and proliferation by interacting with cell surfaces and extracellular matrix molecules (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar). It has been reported that versican interferes with the attachment of cells to various extracellular matrix components such as type I collagen, fibronectin, and laminin (16Yamagata M. Suzuki S. Akiyama S.K. Yamada K.M. Kimata K. J. Biol. Chem. 1989; 264: 8012-8018Abstract Full Text PDF PubMed Google Scholar) and acts to inhibit cell adhesion (17Yamagata M. Saga S. Kato M. Bernfield M. Kimata K. J. Cell Sci. 1993; 106: 55-65Crossref PubMed Google Scholar, 18Yamagata M. Kimata K. J. Cell Sci. 1994; 107: 2581-2590Crossref PubMed Google Scholar). It may also play a role in the formation of tissues that act as barriers to migratory neural crest cells and outgrowing axons during embryonic development (19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). The expression of versican appears to be developmentally regulated in some cases. For example, during hair development, versican is not expressed until the hair follicle starts to grow (20du Cros D.L. LeBaron R.G. Couchman J.R. J. Invest. Dermatol. 1995; 105: 426-431Abstract Full Text PDF PubMed Scopus (109) Google Scholar). Versican expression intensifies with follicle maturation, reaches a maximum at the height of the growth phase, diminishes at the end of the phase, and disappears as the follicle enters the next hair cycle. Thus, versican expression is turned on and off in each cycle, and it appears that its expression correlates with cell differentiation. Furthermore, versican is transiently expressed during mesenchymal condensation. Versican is highly expressed in condensing mesenchyme, but during the transition from mesenchyme to cartilage, the expression of versican is down-regulated and finally is restricted to the periphery of the newly formed cartilage.To study the role of versican in tissue development, we introduced a mini-versican gene product into an in vitro mesenchymal condensation and chondrogenesis model, and we observed that it inhibited mesenchymal differentiation. This was further confirmed using antisense and transfection studies. Studies using versican constructs lacking the EGF-like motif indicated that this motif is responsible for the inhibiting effect.DISCUSSIONVersican is found in significant concentrations in tissues where the cells are actively proliferating, for example, embryonic tissues and the epidermal proliferative zone (3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar, 8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar, 19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). This indicates that versican may be involved in cell growth, and our previous work has indeed confirmed that versican stimulates cell proliferation (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). Since cell growth and differentiation are usually antagonistic, we hypothesized that versican would affect cell differentiation. In this study, we report that versican does inhibit mesenchymal chondrogenesis but not condensation. The inhibition is apparently mediated, at least in part, by the G3 domain of versican and specifically by the EGF-like motifs.To determine the effects of versican, we devised an in vitroassay system using chick mesenchymal cells in culture. Our findings show that such assays are sensitive and require careful calibration of mesenchymal age and cell plating density to detect the effects of versican. After extensive experimentation, we determined that limb buds harvested in stages 22–24 were optimal for our work.In the in vitro assay, cell differentiation was monitored using three separate methods. Morphological changes provided one measure of cell differentiation: as cultures differentiate, they produce characteristic "swirls" (high densities of cells and matrix) which later develop into cartilaginous nodules and increase in size over time. The second method of assessing differentiation involved histochemical techniques. Two major products of chondrocytes are aggrecan and link protein (32Stirpe N.S. Argraves W.S. Goetinck P.F. Dev. Biol. 1987; 124: 77-81Crossref PubMed Scopus (33) Google Scholar, 33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). Alcian blue, a dye that nonspecifically stains glycosaminoglycan chains, easily detects aggrecan that possesses 100–150 chondroitin sulfate and keratin sulfate side chains. Thus, staining cultures with Alcian blue allowed detection of chondrogenesis even at early stages. Third, although aggrecan is a poor choice for monitoring the onset of chondrogenesis by immunoblot analysis as it appears on SDS-PAGE as a large smear over 500 kDa, link protein is a convenient marker for chondrogenesis. Anti-link protein antibody recognizes a discrete 52-kDa protein on an immunoblot, and although link protein appears in most tissues, it is found at high concentrations only in mature cartilage (33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). We did not detect link protein in areas of cell condensation. Since type II collagen is also a major component of cartilage, we have confirmed our results by collagen staining. Results obtained using the above techniques (morphologic analysis, Alcian blue staining, and expression of link protein) were all consistent with the inhibition of chondrogenesis by the mini-versican.In our first studies of the effects of versican on chondrogenesis, we used versican gene product, manufactured by transfected COS-7 or NIH3T3 cells and secreted into their growth media (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). By using this system, however, we could not exclude the possibility that inhibitory effects of versican on differentiation were indirect. The gene product may have interacted with other proteins to produce unidentified factors that may have been secreted into the medium, causing the observed effects. To investigate if versican acts directly, we purified the mini-versican product and demonstrated that the purified product also inhibited chondrogenesis. We used a Ni-NTA affinity column to purify the mini-versican. With extensive washing, we were always able to obtain purified products with undetectable contamination stained by silver. However, the purified products were always diluted during dialysis. The products were not concentrated in order to maintain the products in its active forms. What is important in our assay is that the purified mini-versican, although at a much lower concentration compared with those expressed by COS-7 and mesenchymal cells, inhibited mesenchymal chondrogenesis. We also used transfection and antisense approaches. Results obtained from mesenchymal cell cultures transfected with versican constructs confirmed our hypothesis that the mini-versican itself inhibits differentiation. Moreover, all versican antisense oligonucleotides and versican antisense constructs also inhibited the effect of versican on chondrogenesis. We hypothesize that at the concentration of oligonucleotides used or in the presence of antisense construct, translation of versican mRNA was inhibited.Before cells can differentiate, they must first undergo condensation. The question that arises is whether versican interferes with the differentiation process by preventing condensation. To monitor condensation, PNA, which binds to the extracellular aggregates in condensed mesenchymal cultures (27Aulthouse A.L. Solursh M. Dev. Biol. 1987; 120: 377-384Crossref PubMed Scopus (92) Google Scholar), was used. Treatment with versican or versican antisense oligonucleotides had no obvious effect on the number of PNA-stained foci observed during early stages of treatment. However, we cannot rule out the possibility that mesenchymal cells isolated from stage 22–24 embryos already contain endogenous condensation signals nor that condensation was an automatic response to high culture density. Neither exogenous addition of versican gene product nor versican antisense oligonucleotides affected condensation; however, whereas the gene product also inhibited subsequent differentiation in the culture, treatment with antisense oligonucleotides and antisense construct actually seemed to enhance chondrogenesis. Given that versican stimulates cell proliferation, and versican expression must be down-regulated before chondrogenesis can proceed, it may be that exposure to the versican gene product prevented the initiation of chondrogenesis, whereas blocking expression of versican with antisense oligonucleotides actually triggered a differentiation pathway.Given, then, that versican does not function by blocking events prerequisite to differentiation, such as condensation, but seems to inhibit the differentiation process itself, we were interested in characterizing the mechanism of its activity. By treating mesenchymal cultures with the gene products of constructs expressing various domains of the versican molecule, we found in the present study that the G3 domain of versican alone can inhibit differentiation. This domain comprises three separate sections as follows: a set of epidermal growth factor-like motifs, a carbohydrate recognition sequence, and a complement-binding protein-like sequence. When cells were treated with the products of a mini-versican construct lacking the EGF-like motifs or with aggrecan G3 domain (which does not contain EGF-like motif), the culture underwent chondrogenesis, implying that the EGF-like motifs were involved in the inhibition. These results were confirmed by direct transfection of mesenchymal cells with the above constructs. Consistent with our results, a protein containing EGF-like repeats has also been reported to prevent differentiation in adipocyte precursors (29Smas C., M. Sui H.S. Cell. 1993; 73: 725-734Abstract Full Text PDF PubMed Scopus (559) Google Scholar). Nor is this inhibition directly related to the ability of EGF to stimulate proliferation: EGF's inhibition of differentiation appears to operate via a separate mechanism (34Serrero G. Lepak N. Int. J. Obes. 1996; 20 (compare): 58-64PubMed Google Scholar). In our experiments too, the inhibitory effects of versican are distinct and not directly related to its stimulatory effects, since the amount of versican gene product required to prevent differentiation was less than the amount required to stimulate mesenchymal proliferation (data not shown). It should be mentioned that the EGF-like motifs of versican are necessary for the inhibition of chondrogenesis but are by themselves not sufficient for this function since a chimeric construct containing the EGF-like motifs of versican and the G3 domain of aggrecan only partially inhibited chondrogenesis as compared with the vG3 domain construct. These results suggest that other motifs in the G3 domain are involved in the effect of versican on chondrogenesis. We are currently studying the roles of other motifs.Evidence from this study and from other studies suggests that the proteoglycan versican may play an important and complex role in cell growth and differentiation. It simulates cell proliferation, both directly, through its G1 and EGF-like subdomains, and indirectly; and it inhibits cell differentiation, an effect mediated by its EGF-like subdomains. The physiological significance of these findings remains to be determined. Versican is expressed in a variety of tissues. High concentrations are found in embryonic tissues, such as human embryonic lung (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar), the mesenchymal cell condensation area of limb buds (2Kimata K. Oike Y. Tani K. Shinomura T. Yamagata M. Uritani M. Suzuki S. J. Biol. Chem. 1986; 261: 13517-13525Abstract Full Text PDF PubMed Google Scholar, 3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar), the perinotochordal mesenchyme between the notochord and neural tube, and basement membranes facing the neuroepithelial cells of chicks (4Yamagata M. Shinomura T. Kimata K. Anat. Embryol. 1993; 187: 433-444Crossref PubMed Scopus (82) Google Scholar). It is also present in embryonic aorta, lung, cornea, and skeletal muscle (4Yamagata M. Shinomura T. Kimata K. Anat. Embryol. 1993; 187: 433-444Crossref PubMed Scopus (82) Google Scholar). In adult tissues, versican is detected in the loose connective tissue of various organs including most smooth muscles, the central and peripheral nervous systems, the luminal surface of glandular epithelia (5Bode-Lesniewska B. Dours-Zimmermann M.T. Odermattm B.F. Briner J. Heitz P.U. Zimmermann D.R. J. Histochem. Cytochem. 1996; 44: 303-312Crossref PubMed Scopus (162) Google Scholar), blood vessels (6Yao L.Y. Moody C. Schonherr E. Wight T.N. Sandell L.J. Matrix Biol. 1994; 14: 213-225Crossref PubMed Scopus (104) Google Scholar), vessels of brain tumors (7Paulus W. Baur I. Dours-Zimmermann M.T. Zimmerman D.R. J. Neuropath. Exp. Neurol. 1996; 55: 528-533Crossref PubMed Scopus (94) Google Scholar), dermis, and in the proliferative zone of the epidermis (8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar). Versican (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 9Shinomura T. Nishida Y. Ito K. Kimata K. J. Biol. Chem. 1993; 268: 14461-14469Abstract Full Text PDF PubMed Google Scholar) is a member of the large aggregating chondroitin sulfate proteoglycan family (10Margolis R.U. Margolis R.K. Methods Enzymol. 1994; 245: 105-126Crossref PubMed Scopus (88) Google Scholar), which also includes aggrecan, neurocan, and brevican. All contain G1 domains at their amino termini and G3 domains at their carboxyl termini. A varying number of chondroitin sulfate side chains are attached to a central chondroitin sulfate bearing sequence; in versican, 12–15 chondroitin sulfate side chains are covalently attached to this sequence (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 11Krusius T. Gehlsen K.R. Ruoslahti E. J. Biol. Chem. 1987; 262: 13120-13125Abstract Full Text PDF PubMed Google Scholar). This central sequence contains two alternatively spliced domains, glycosaminoglycan-α and glycosaminoglycan-β (12Dours-Zimmermann M.T. Zimmermann D.R. J. Biol. Chem. 1994; 269: 32992-32998Abstract Full Text PDF PubMed Google Scholar, 13Naso M.F. Zimmermann D.R. Iozzo R.V. J. Biol. Chem. 1994; 269: 32999-33008Abstract Full Text PDF PubMed Google Scholar, 14Naso M.F. Morgan J.L. Buchberg A.M. Siracusa L.D. Iozzo R.V. Genomics. 1995; 29: 297-300Crossref PubMed Scopus (29) Google Scholar). The functions of these proteoglycans remain elusive. Different domains may be involved in different cellular processes. The G1 domain of versican, as well as that of other members of that family, binds hyaluronan and may participate in matrix assembly and cell-cell and cell-matrix interactions. The G3 domain, consisting of lectin-like (also called carbohydrate regulatory domain), epidermal growth factor-like (EGF1-like), and complement binding protein motifs, is structurally similar to the selectin family (15Springer T.A. Lasky L.A. Nature. 1991; 349: 196-197Crossref PubMed Scopus (411) Google Scholar). But whereas selectins play a role in mediating cell adhesion, no such function has been identified for the G3 domain of versican. It is possible that the EGF-like and lectin-like motifs are involved in intercellular signaling or cell recognition processes. The chondroitin sulfate chains of versican are reported to inhibit cell adhesion (16Yamagata M. Suzuki S. Akiyama S.K. Yamada K.M. Kimata K. J. Biol. Chem. 1989; 264: 8012-8018Abstract Full Text PDF PubMed Google Scholar, 17Yamagata M. Saga S. Kato M. Bernfield M. Kimata K. J. Cell Sci. 1993; 106: 55-65Crossref PubMed Google Scholar). Thus, versican is suspected to play a role in cellular attachment, migration, and proliferation by interacting with cell surfaces and extracellular matrix molecules (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar). It has been reported that versican interferes with the attachment of cells to various extracellular matrix components such as type I collagen, fibronectin, and laminin (16Yamagata M. Suzuki S. Akiyama S.K. Yamada K.M. Kimata K. J. Biol. Chem. 1989; 264: 8012-8018Abstract Full Text PDF PubMed Google Scholar) and acts to inhibit cell adhesion (17Yamagata M. Saga S. Kato M. Bernfield M. Kimata K. J. Cell Sci. 1993; 106: 55-65Crossref PubMed Google Scholar, 18Yamagata M. Kimata K. J. Cell Sci. 1994; 107: 2581-2590Crossref PubMed Google Scholar). It may also play a role in the formation of tissues that act as barriers to migratory neural crest cells and outgrowing axons during embryonic development (19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). The expression of versican appears to be developmentally regulated in some cases. For example, during hair development, versican is not expressed until the hair follicle starts to grow (20du Cros D.L. LeBaron R.G. Couchman J.R. J. Invest. Dermatol. 1995; 105: 426-431Abstract Full Text PDF PubMed Scopus (109) Google Scholar). Versican expression intensifies with follicle maturation, reaches a maximum at the height of the growth phase, diminishes at the end of the phase, and disappears as the follicle enters the next hair cycle. Thus, versican expression is turned on and off in each cycle, and it appears that its expression correlates with cell differentiation. Furthermore, versican is transiently expressed during mesenchymal condensation. Versican is highly expressed in condensing mesenchyme, but during the transition from mesenchyme to cartilage, the expression of versican is down-regulated and finally is restricted to the periphery of the newly formed cartilage. To study the role of versican in tissue development, we introduced a mini-versican gene product into an in vitro mesenchymal condensation and chondrogenesis model, and we observed that it inhibited mesenchymal differentiation. This was further confirmed using antisense and transfection studies. Studies using versican constructs lacking the EGF-like motif indicated that this motif is responsible for the inhibiting effect. DISCUSSIONVersican is found in significant concentrations in tissues where the cells are actively proliferating, for example, embryonic tissues and the epidermal proliferative zone (3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar, 8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar, 19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). This indicates that versican may be involved in cell growth, and our previous work has indeed confirmed that versican stimulates cell proliferation (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). Since cell growth and differentiation are usually antagonistic, we hypothesized that versican would affect cell differentiation. In this study, we report that versican does inhibit mesenchymal chondrogenesis but not condensation. The inhibition is apparently mediated, at least in part, by the G3 domain of versican and specifically by the EGF-like motifs.To determine the effects of versican, we devised an in vitroassay system using chick mesenchymal cells in culture. Our findings show that such assays are sensitive and require careful calibration of mesenchymal age and cell plating density to detect the effects of versican. After extensive experimentation, we determined that limb buds harvested in stages 22–24 were optimal for our work.In the in vitro assay, cell differentiation was monitored using three separate methods. Morphological changes provided one measure of cell differentiation: as cultures differentiate, they produce characteristic "swirls" (high densities of cells and matrix) which later develop into cartilaginous nodules and increase in size over time. The second method of assessing differentiation involved histochemical techniques. Two major products of chondrocytes are aggrecan and link protein (32Stirpe N.S. Argraves W.S. Goetinck P.F. Dev. Biol. 1987; 124: 77-81Crossref PubMed Scopus (33) Google Scholar, 33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). Alcian blue, a dye that nonspecifically stains glycosaminoglycan chains, easily detects aggrecan that possesses 100–150 chondroitin sulfate and keratin sulfate side chains. Thus, staining cultures with Alcian blue allowed detection of chondrogenesis even at early stages. Third, although aggrecan is a poor choice for monitoring the onset of chondrogenesis by immunoblot analysis as it appears on SDS-PAGE as a large smear over 500 kDa, link protein is a convenient marker for chondrogenesis. Anti-link protein antibody recognizes a discrete 52-kDa protein on an immunoblot, and although link protein appears in most tissues, it is found at high concentrations only in mature cartilage (33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). We did not detect link protein in areas of cell condensation. Since type II collagen is also a major component of cartilage, we have confirmed our results by collagen staining. Results obtained using the above techniques (morphologic analysis, Alcian blue staining, and expression of link protein) were all consistent with the inhibition of chondrogenesis by the mini-versican.In our first studies of the effects of versican on chondrogenesis, we used versican gene product, manufactured by transfected COS-7 or NIH3T3 cells and secreted into their growth media (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). By using this system, however, we could not exclude the possibility that inhibitory effects of versican on differentiation were indirect. The gene product may have interacted with other proteins to produce unidentified factors that may have been secreted into the medium, causing the observed effects. To investigate if versican acts directly, we purified the mini-versican product and demonstrated that the purified product also inhibited chondrogenesis. We used a Ni-NTA affinity column to purify the mini-versican. With extensive washing, we were always able to obtain purified products with undetectable contamination stained by silver. However, the purified products were always diluted during dialysis. The products were not concentrated in order to maintain the products in its active forms. What is important in our assay is that the purified mini-versican, although at a much lower concentration compared with those expressed by COS-7 and mesenchymal cells, inhibited mesenchymal chondrogenesis. We also used transfection and antisense approaches. Results obtained from mesenchymal cell cultures transfected with versican constructs confirmed our hypothesis that the mini-versican itself inhibits differentiation. Moreover, all versican antisense oligonucleotides and versican antisense constructs also inhibited the effect of versican on chondrogenesis. We hypothesize that at the concentration of oligonucleotides used or in the presence of antisense construct, translation of versican mRNA was inhibited.Before cells can differentiate, they must first undergo condensation. The question that arises is whether versican interferes with the differentiation process by preventing condensation. To monitor condensation, PNA, which binds to the extracellular aggregates in condensed mesenchymal cultures (27Aulthouse A.L. Solursh M. Dev. Biol. 1987; 120: 377-384Crossref PubMed Scopus (92) Google Scholar), was used. Treatment with versican or versican antisense oligonucleotides had no obvious effect on the number of PNA-stained foci observed during early stages of treatment. However, we cannot rule out the possibility that mesenchymal cells isolated from stage 22–24 embryos already contain endogenous condensation signals nor that condensation was an automatic response to high culture density. Neither exogenous addition of versican gene product nor versican antisense oligonucleotides affected condensation; however, whereas the gene product also inhibited subsequent differentiation in the culture, treatment with antisense oligonucleotides and antisense construct actually seemed to enhance chondrogenesis. Given that versican stimulates cell proliferation, and versican expression must be down-regulated before chondrogenesis can proceed, it may be that exposure to the versican gene product prevented the initiation of chondrogenesis, whereas blocking expression of versican with antisense oligonucleotides actually triggered a differentiation pathway.Given, then, that versican does not function by blocking events prerequisite to differentiation, such as condensation, but seems to inhibit the differentiation process itself, we were interested in characterizing the mechanism of its activity. By treating mesenchymal cultures with the gene products of constructs expressing various domains of the versican molecule, we found in the present study that the G3 domain of versican alone can inhibit differentiation. This domain comprises three separate sections as follows: a set of epidermal growth factor-like motifs, a carbohydrate recognition sequence, and a complement-binding protein-like sequence. When cells were treated with the products of a mini-versican construct lacking the EGF-like motifs or with aggrecan G3 domain (which does not contain EGF-like motif), the culture underwent chondrogenesis, implying that the EGF-like motifs were involved in the inhibition. These results were confirmed by direct transfection of mesenchymal cells with the above constructs. Consistent with our results, a protein containing EGF-like repeats has also been reported to prevent differentiation in adipocyte precursors (29Smas C., M. Sui H.S. Cell. 1993; 73: 725-734Abstract Full Text PDF PubMed Scopus (559) Google Scholar). Nor is this inhibition directly related to the ability of EGF to stimulate proliferation: EGF's inhibition of differentiation appears to operate via a separate mechanism (34Serrero G. Lepak N. Int. J. Obes. 1996; 20 (compare): 58-64PubMed Google Scholar). In our experiments too, the inhibitory effects of versican are distinct and not directly related to its stimulatory effects, since the amount of versican gene product required to prevent differentiation was less than the amount required to stimulate mesenchymal proliferation (data not shown). It should be mentioned that the EGF-like motifs of versican are necessary for the inhibition of chondrogenesis but are by themselves not sufficient for this function since a chimeric construct containing the EGF-like motifs of versican and the G3 domain of aggrecan only partially inhibited chondrogenesis as compared with the vG3 domain construct. These results suggest that other motifs in the G3 domain are involved in the effect of versican on chondrogenesis. We are currently studying the roles of other motifs.Evidence from this study and from other studies suggests that the proteoglycan versican may play an important and complex role in cell growth and differentiation. It simulates cell proliferation, both directly, through its G1 and EGF-like subdomains, and indirectly; and it inhibits cell differentiation, an effect mediated by its EGF-like subdomains. The physiological significance of these findings remains to be determined. Versican is found in significant concentrations in tissues where the cells are actively proliferating, for example, embryonic tissues and the epidermal proliferative zone (3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar, 8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar, 19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). This indicates that versican may be involved in cell growth, and our previous work has indeed confirmed that versican stimulates cell proliferation (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). Since cell growth and differentiation are usually antagonistic, we hypothesized that versican would affect cell differentiation. In this study, we report that versican does inhibit mesenchymal chondrogenesis but not condensation. The inhibition is apparently mediated, at least in part, by the G3 domain of versican and specifically by the EGF-like motifs. To determine the effects of versican, we devised an in vitroassay system using chick mesenchymal cells in culture. Our findings show that such assays are sensitive and require careful calibration of mesenchymal age and cell plating density to detect the effects of versican. After extensive experimentation, we determined that limb buds harvested in stages 22–24 were optimal for our work. In the in vitro assay, cell differentiation was monitored using three separate methods. Morphological changes provided one measure of cell differentiation: as cultures differentiate, they produce characteristic "swirls" (high densities of cells and matrix) which later develop into cartilaginous nodules and increase in size over time. The second method of assessing differentiation involved histochemical techniques. Two major products of chondrocytes are aggrecan and link protein (32Stirpe N.S. Argraves W.S. Goetinck P.F. Dev. Biol. 1987; 124: 77-81Crossref PubMed Scopus (33) Google Scholar, 33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). Alcian blue, a dye that nonspecifically stains glycosaminoglycan chains, easily detects aggrecan that possesses 100–150 chondroitin sulfate and keratin sulfate side chains. Thus, staining cultures with Alcian blue allowed detection of chondrogenesis even at early stages. Third, although aggrecan is a poor choice for monitoring the onset of chondrogenesis by immunoblot analysis as it appears on SDS-PAGE as a large smear over 500 kDa, link protein is a convenient marker for chondrogenesis. Anti-link protein antibody recognizes a discrete 52-kDa protein on an immunoblot, and although link protein appears in most tissues, it is found at high concentrations only in mature cartilage (33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). We did not detect link protein in areas of cell condensation. Since type II collagen is also a major component of cartilage, we have confirmed our results by collagen staining. Results obtained using the above techniques (morphologic analysis, Alcian blue staining, and expression of link protein) were all consistent with the inhibition of chondrogenesis by the mini-versican. In our first studies of the effects of versican on chondrogenesis, we used versican gene product, manufactured by transfected COS-7 or NIH3T3 cells and secreted into their growth media (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). By using this system, however, we could not exclude the possibility that inhibitory effects of versican on differentiation were indirect. The gene product may have interacted with other proteins to produce unidentified factors that may have been secreted into the medium, causing the observed effects. To investigate if versican acts directly, we purified the mini-versican product and demonstrated that the purified product also inhibited chondrogenesis. We used a Ni-NTA affinity column to purify the mini-versican. With extensive washing, we were always able to obtain purified products with undetectable contamination stained by silver. However, the purified products were always diluted during dialysis. The products were not concentrated in order to maintain the products in its active forms. What is important in our assay is that the purified mini-versican, although at a much lower concentration compared with those expressed by COS-7 and mesenchymal cells, inhibited mesenchymal chondrogenesis. We also used transfection and antisense approaches. Results obtained from mesenchymal cell cultures transfected with versican constructs confirmed our hypothesis that the mini-versican itself inhibits differentiation. Moreover, all versican antisense oligonucleotides and versican antisense constructs also inhibited the effect of versican on chondrogenesis. We hypothesize that at the concentration of oligonucleotides used or in the presence of antisense construct, translation of versican mRNA was inhibited. Before cells can differentiate, they must first undergo condensation. The question that arises is whether versican interferes with the differentiation process by preventing condensation. To monitor condensation, PNA, which binds to the extracellular aggregates in condensed mesenchymal cultures (27Aulthouse A.L. Solursh M. Dev. Biol. 1987; 120: 377-384Crossref PubMed Scopus (92) Google Scholar), was used. Treatment with versican or versican antisense oligonucleotides had no obvious effect on the number of PNA-stained foci observed during early stages of treatment. However, we cannot rule out the possibility that mesenchymal cells isolated from stage 22–24 embryos already contain endogenous condensation signals nor that condensation was an automatic response to high culture density. Neither exogenous addition of versican gene product nor versican antisense oligonucleotides affected condensation; however, whereas the gene product also inhibited subsequent differentiation in the culture, treatment with antisense oligonucleotides and antisense construct actually seemed to enhance chondrogenesis. Given that versican stimulates cell proliferation, and versican expression must be down-regulated before chondrogenesis can proceed, it may be that exposure to the versican gene product prevented the initiation of chondrogenesis, whereas blocking expression of versican with antisense oligonucleotides actually triggered a differentiation pathway. Given, then, that versican does not function by blocking events prerequisite to differentiation, such as condensation, but seems to inhibit the differentiation process itself, we were interested in characterizing the mechanism of its activity. By treating mesenchymal cultures with the gene products of constructs expressing various domains of the versican molecule, we found in the present study that the G3 domain of versican alone can inhibit differentiation. This domain comprises three separate sections as follows: a set of epidermal growth factor-like motifs, a carbohydrate recognition sequence, and a complement-binding protein-like sequence. When cells were treated with the products of a mini-versican construct lacking the EGF-like motifs or with aggrecan G3 domain (which does not contain EGF-like motif), the culture underwent chondrogenesis, implying that the EGF-like motifs were involved in the inhibition. These results were confirmed by direct transfection of mesenchymal cells with the above constructs. Consistent with our results, a protein containing EGF-like repeats has also been reported to prevent differentiation in adipocyte precursors (29Smas C., M. Sui H.S. Cell. 1993; 73: 725-734Abstract Full Text PDF PubMed Scopus (559) Google Scholar). Nor is this inhibition directly related to the ability of EGF to stimulate proliferation: EGF's inhibition of differentiation appears to operate via a separate mechanism (34Serrero G. Lepak N. Int. J. Obes. 1996; 20 (compare): 58-64PubMed Google Scholar). In our experiments too, the inhibitory effects of versican are distinct and not directly related to its stimulatory effects, since the amount of versican gene product required to prevent differentiation was less than the amount required to stimulate mesenchymal proliferation (data not shown). It should be mentioned that the EGF-like motifs of versican are necessary for the inhibition of chondrogenesis but are by themselves not sufficient for this function since a chimeric construct containing the EGF-like motifs of versican and the G3 domain of aggrecan only partially inhibited chondrogenesis as compared with the vG3 domain construct. These results suggest that other motifs in the G3 domain are involved in the effect of versican on chondrogenesis. We are currently studying the roles of other motifs. Evidence from this study and from other studies suggests that the proteoglycan versican may play an important and complex role in cell growth and differentiation. It simulates cell proliferation, both directly, through its G1 and EGF-like subdomains, and indirectly; and it inhibits cell differentiation, an effect mediated by its EGF-like subdomains. The physiological significance of these findings remains to be determined. We are grateful to Dr. Paul F. Goetinck for the monoclonal antibody 4B6. We thank Dr. S. Jothy for helpful comments and Wendy Hu for technical assistance.
What problem does this paper attempt to address?
-
Versican Modulates Embryonic Chondrocyte Morphology Via the Epidermal Growth Factor-Like Motifs in G3.
Y Zhang,YJ Wu,L Cao,V Lee,LW Chen,ZS Lin,C Kiani,ME Adams,BB Yang
DOI: https://doi.org/10.1006/excr.2000.5095
IF: 4.145
2001-01-01
Experimental Cell Research
Abstract:This investigation was designed to characterize the effect of the extracellular matrix molecule versican on chondrocyte morphology, using the well-studied chondrocyte cell culture system. When cultured chondrocytes reverted or "dedifferentiated" to a fibroblast-like morphology, we found that versican expression was significantly enhanced. Transfection of chondrocytes, isolated from embryonic chicken sterna, with a chicken miniversican construct accelerated the reversion process, while expression of an antisense construct inhibited it. A mutant miniversican lacking two epidermal growth factor-like motifs (versicanDeltaEGF) promoted differentiation, as shown by morphological changes and changes in the expression of other extracellular matrix molecules. A truncated versican mutant, the G3DeltaEGF, a G3 domain lacking its two epidermal growth factor-like motifs, also enhanced differentiation. This effect is related to G3DeltaEGF-induced change in cytoskeleton, since transfected cells exhibited misassembly of actin filaments. This article thus provides the first evidence that versican modulates chondrocyte morphology via changes in cytoskeletal structure, and may imply that extracellular matrix molecules play an important role in cell differentiation.
-
Stage-dependent effect of TGF-beta1 on chondrogenic differentiation of human embryonic stem cells.
Zheng Yang,Lin Sui,Wei Seong Toh,Eng Hin Lee,Tong Cao
DOI: https://doi.org/10.1089/scd.2008.0219
2009-01-01
Stem Cells and Development
Abstract:Transforming growth factor-beta (TGF-beta) is known to be a potent inducer of stem cell chondrogenic differentiation. Transforming growth factor-beta/activin/nodal-signaling pathway has also been shown to be involved in maintaining the pluripotency of embryonic stem cells (ESCs). In this study, the effect of TGF-beta 1 in chondrogenic differentiation of ESCs was examined both with undifferentiated ESCs that bypassed classical embryoid body (EB) formation, and on 5-day EB-derived cells. The effect of TGF-beta 1 was compared to cells differentiated in serum-free chondrogenic basal medium without growth factor supplement. Analysis by real-time polymerase chain reaction (PCR), type II collagen enzyme-linked immunosorbent assay, sulfated glycoaminoglycan quantification and fluorescence immunostaining demonstrated substantial chondrogenic differentiation of ESCs regardless of EB formation in the absence of the growth factor. Addition of TGF-beta 1 significantly inhibited chondrogenic gene expression and collagen deposition with a more potent effect on the cells that bypassed EB formation. Our study using a TGF-beta/activin/nodal-signaling inhibitor suggested that TGF-beta inhibited early chondrogenic induction but was required at the later stage of differentiation, which was also reflected in the enhancing effect of TGF-beta 1 on chondrogenic development at later time points in EB-derived cells. Analysis of the pluripotency markers demonstrated sustained Oct4 and Nanog expression in the presence of TGF-beta 1 with Oct4-positive cells detected in subpopulations of the differentiated culture. Our results suggest that TGF-beta 1 suppresses ESC chondrogenic induction and the degree of suppression is dependent on the differentiation-stage of the ESC. Transforming growth factor-beta signaling, however, is required for functional chondrogenic development of ESC. Our finding that TGF-beta can sustain an undifferentiated population of human ESCs within the differentiation culture suggests that caution should be exercised when using this growth factor as an ESC chondrogenic inducer and highlights the importance of a selection protocol for chondroprogenitor cells to avoid possible teratoma formation in vivo.
-
G3 Domains of Aggrecan and Pg-M/Versican Form Intermolecular Disulfide Bonds That Stabilize Cell-Matrix Interaction
LW Chen,BL Yang,YJ Wu,A Yee,BB Yang
DOI: https://doi.org/10.1021/bi034335f
IF: 3.321
2003-01-01
Biochemistry
Abstract:The extracellular matrix plays a critical role in maintaining tissue integrity. Among the matrix molecules, the large aggregating chondroitin sulfate proteoglycans are the major structural molecules and are the primary contributors to the stability for some tissues such as cartilage. The notable exceptions are nanomelic cartilage and arthritic cartilage: the former contains a point mutation leading to a stop codon before translating to the C-terminal G3 domain; the latter contains a large proportion of aggrecan from which the G3 domain has been cleaved. These phenomena suggest that the G3 domain may be important in cartilage stability. Here, we demonstrated for the first time that the G3 domains of aggrecan and another proteoglycan, PG-M/versican, formed intermolecular disulfide bonds, and all subdomains were involved. Further studies indicated that each of the 10 cysteine residues of the aggrecan G3 domain could potentially form intermolecular disulfide bonds in vitro. The disulfide bonds were disrupted in the presence of reducing reagent beta-mercaptoethanol and dithiothreitol. As a result, normal chondrocyte-matrix interaction was disrupted, and the structure of the extracellular matrix was altered. Furthermore, disruption of disulfide bonds also reduced the role of PG-M/versican G3 domain in mediating cell adhesion. Our study provides strong evidence of the importance of proteoglycan interactions through intermolecular disulfide bonds in cartilage firmness and cell-matrix stability.
-
Versican—A Critical Extracellular Matrix Regulator of Immunity and Inflammation
Thomas N. Wight,Inkyung Kang,Stephen P. Evanko,Ingrid A. Harten,Mary Y. Chang,Oliver M. T. Pearce,Carys E. Allen,Charles W. Frevert
DOI: https://doi.org/10.3389/fimmu.2020.00512
IF: 7.3
2020-03-24
Frontiers in Immunology
Abstract:The extracellular matrix (ECM) proteoglycan, versican increases along with other ECM versican binding molecules such as hyaluronan, tumor necrosis factor stimulated gene-6 (TSG-6), and inter alpha trypsin inhibitor (IαI) during inflammation in a number of different diseases such as cardiovascular and lung disease, autoimmune diseases, and several different cancers. These interactions form stable scaffolds which can act as "landing strips" for inflammatory cells as they invade tissue from the circulation. The increase in versican is often coincident with the invasion of leukocytes early in the inflammatory process. Versican interacts with inflammatory cells either indirectly via hyaluronan or directly via receptors such as CD44, P-selectin glycoprotein ligand-1 (PSGL-1), and toll-like receptors (TLRs) present on the surface of immune and non-immune cells. These interactions activate signaling pathways that promote the synthesis and secretion of inflammatory cytokines such as TNFα, IL-6, and NFκB. Versican also influences inflammation by interacting with a variety of growth factors and cytokines involved in regulating inflammation thereby influencing their bioavailability and bioactivity. Versican is produced by multiple cell types involved in the inflammatory process. Conditional total knockout of versican in a mouse model of lung inflammation demonstrated significant reduction in leukocyte invasion into the lung and reduced inflammatory cytokine expression. While versican produced by stromal cells tends to be pro-inflammatory, versican expressed by myeloid cells can create anti-inflammatory and immunosuppressive microenvironments. Inflammation in the tumor microenvironment often contains elevated levels of versican. Perturbing the accumulation of versican in tumors can inhibit inflammation and tumor progression in some cancers. Thus versican, as a component of the ECM impacts immunity and inflammation through regulating immune cell trafficking and activation. Versican is emerging as a potential target in the control of inflammation in a number of different diseases.
immunology
-
The Roles of Versican V 1 and V 2 Isoforms in Cell Proliferation and Apoptosis
BB Yang
DOI: https://doi.org/10.1091/mbc.e04-04-0295
2005-01-01
Molecular Biology of the Cell
Abstract:Versican is a large chondroitin sulfate proteoglycan belonging to the lectican family. Alternative splicing of versican generates at least four isoforms named V0, V1, V2, and V3. We have shown that the versican V1 isoform not only enhanced cell proliferation, but also modulated cell cycle progression and protected the cells from apoptosis. Futhermore, the V1 isoform was able to not only activate proto-oncogene EGFR expression and modulate its downstream signaling pathway, but also induce p27 degradation and enhance CDK2 kinase activity. As well, the V1 isoform down-regulated the expression of the proapoptotic protein Bad. By contrast, the V2 isoform exhibited opposite biological activities by inhibiting cell proliferation and down-regulated the expression of EGFR and cyclin A. Furthermore, V2 did not contribute apoptotic resistance to the cells. In light of these results, we are reporting opposite functions for the two versican isoforms whose expression is differentially regulated. Our studies suggest that the roles of these two isoforms are associated with the subdomains CSβ and CSα, respectively. These results were confirmed by silencing the expression of versican V1 with small interfering RNA (siRNA), which abolished V1-enhanced cell proliferation and V1-induced reduction of apoptosis.
-
Identification of the Motif in Versican G3 Domain That Plays a Dominant-Negative Effect on Astrocytoma Cell Proliferation Through Inhibiting Versican Secretion and Binding.
YJ Wu,Y Zhang,L Cao,LW Chen,V Lee,PS Zheng,C Kiani,ME Adams,LC Ang,F Paiwand,BB Yang
DOI: https://doi.org/10.1074/jbc.m100618200
2001-01-01
Abstract:This study was designed to investigate the mechanisms by which mutant versican constructs play a dominant-negative effect on astrocytoma cell proliferation. Although a mini-versican or a versican G3 construct promoted growth of U87 astrocytoma cells, a mini-versican lacking epidermal growth factor (EGF) motifs (versicanDeltaEGF) and a G3 mutant (G3DeltaEGF) exerted a dominant-negative effect on cell proliferation. G3DeltaEGF-transfected cells formed smaller colonies, arrested cell cycle at G(1) phase, inhibited expression of cell cycle proteins cdk4 and cyclin D1, and contained multiple nucleoli. In cell surface binding assays, G3 products expressed in COS-7 cells and bacteria bound to U87 cell surface. G3DeltaEGF products exhibited decreased binding activity, but higher levels of G3DeltaEGF products were able to inhibit the binding of G3 to the cell surface. G3DeltaEGF expression inhibited secretion of endogenous versican in astrocytoma cells and also inhibited the secretion of mini-versican in COS-7 cells co-transfected with the mini-versican and G3DeltaEGF constructs. The effect seems to depend on the expression efficiency of G3DeltaEGF, and it occurred via the carbohydrate recognition domain.
-
The Interaction of Versican with Its Binding Partners
Yao Jiong WU,David P LA PIERRE,Jin WU,Albert J YEE,Burton B YANG
DOI: https://doi.org/10.1038/sj.cr.7290318
IF: 44.1
2005-01-01
Cell Research
Abstract:Versican belongs to the family of the large aggregating chondroitin sulfate proteoglycans located primarily within the extracellular matrix (ECM). Versican, like other members of its family, has unique N- and C-terminal globular regions, each with multiple motifs. A large glycosaminoglycan-binding region lies between them. This review will begin by outlining these structures, in the context of ECM proteoglycans. The diverse binding partners afforded to versican by virtue of its modular design will then be examined. These include ECM components, such as hyaluronan, type I collagen, tenascin-R, fibulin-1, and -2, fibrillin-1, fibronectin, P- and L-selectins, and chemokines. Versican also binds to the cell surface proteins CD44, integrin β1, epidermal growth factor receptor, and P-selectin glycoprotein ligand-1. These multiple interactors play important roles in cell behaviour, and the roles of versican in modulating such processes are discussed.
-
Activin A Promotes Hyaluronan Production and Upregulates Versican Expression in Human Granulosa Cells?
Shen Tian,Han Zhang,Hsun-Ming Chang,Christian Klausen,He-Feng Huang,Min Jin,Peter C. K. Leung
DOI: https://doi.org/10.1093/biolre/ioac070
2022-01-01
Biology of Reproduction
Abstract:Hyaluronan is a structural component of the expanded cumulus matrix, and hyaluronan synthase 2 is the major enzyme for the synthesis of hyaluronan in humans. Versican cross-links the hyaluronan-rich matrix to cumulus cells and is critical for successful ovulation. Activin A is a critical intrafollicular regulator of ovarian function. Although activin A has been shown to promote cumulus matrix expansion in mice, the functional role of activin A in the regulation of cumulus expansion in the human ovary remains to be elucidated. Using primary and immortalized human granulosa-lutein cells as study models, we provide the first data showing that activin A increased the production of hyaluronan by upregulating the expression of hyaluronan synthase 2 in these cells. Additionally, activin A also promoted the expression of the hyaluronan-binding protein versican. Moreover, using inhibitor- and small interfering RNA-mediated inhibition approaches, we found that these stimulatory effects of activin A are most likely mediated through the type I receptor activin receptor-like kinase (ALK4)-mediated Sma- and Mad-related protein (SMAD2)/SMAD3-SMAD4 signaling pathway. Notably, the chromatin immunoprecipitation analyses demonstrated that SMAD4 could bind to human hyaluronan synthase 2 and VERSICAN promoters. The results obtained from this in vitro study suggest that locally produced activin A plays a functional role in the regulation of hyaluronan production and stabilization in human granulosa-lutein cells.
-
Versican Expression Is Associated With Chamber Specification, Septation, and Valvulogenesis in the Developing Mouse Heart
Deborah J. Henderson,Andrew J. Copp
DOI: https://doi.org/10.1161/01.res.83.5.523
IF: 23.213
1998-09-07
Circulation Research
Abstract:Abstract —The versican (PG-M) gene encodes a chondroitin sulfate proteoglycan that is nonpermissive for cell migration and appears in association with slow cell proliferation and cytodifferentiation. Using the techniques of in situ hybridization and immunocytochemistry on sectioned mouse embryos, we found that the mRNA and protein for versican show similar distributions and are expressed in a dynamic pattern during development of the heart. Versican exhibits generalized expression in the tubular heart but becomes rapidly downregulated in the atrium and exhibits higher transcript levels on the right side of the ventricular chamber than the left, before the onset of ventricular septation. Versican is expressed strongly in the trabeculated ventricular myocardium, whereas the compact proliferative zone has lower transcript abundance. It is expressed in the outer layers and on the crest of the ventricular septum and is prominent on the mesenchymal cap of the primary atrial septum. Versican is particularly strongly expressed in the endocardial cushions of the atrioventricular and outflow tract regions and in the atrioventricular, semilunar, and venous valves. This study raises the possibility that versican may be involved in specification of the ventricular chambers, in growth and fusion of the atrial and ventricular septa, and in the transformation from epithelium to mesenchyme that characterizes development of the endocardial cushions. Versican may be a key participant in cardiogenesis, responding to the many diffusible signals that mediate interactions between the developing endocardium and myocardium.
cardiac & cardiovascular systems,peripheral vascular disease,hematology
-
Versican/PG-M G3 domain promotes tumor growth and angiogenesis.
Peng-Sheng Zheng,Jianping Wen,Lee Cyn Ang,Wang Sheng,Alicia Viloria-Petit,Yelina Wang,Yaojiong Wu,Robert S Kerbel,Burton B Yang
DOI: https://doi.org/10.1096/fj.03-0545fje
2004-01-01
Abstract:Versican/PG-M is an extracellular matrix proteoglycan, expression of which is elevated in a variety of human tumors. The significance of this change is unclear. Here we show that versican G3-containing fragments are present at high levels in human astrocytoma. Expression of a versican G3 construct in U87 astrocytoma cells enhances colony growth in soft agarose gel and tumor growth and blood vessel formation in nude mice. The G3-containing medium enhances endothelial cell adhesion, proliferation, and migration. G3-expressing cells and tumors formed by these cells express increased levels of fibronectin and vascular endothelial growth factor (VEGF). Furthermore, the G3 domain directly binds to fibronectin and forms a complex together with VEGF. In the presence of these three molecules, endothelial cell adhesion, proliferation, and migration were found to be significantly enhanced. Removal of the complex containing these molecules reverses these processes. Taken together, these findings implicate G3 as a modifier of tumor growth and angiogenesis and suggest a new avenue for development of anticancer and anti-angiogenic therapies based on targeting versican G3 fragments.
-
The Role of Versican G3 Domain in Regulating Breast Cancer Cell Motility Including Effects on Osteoblast Cell Growth and Differentiation in Vitro – Evaluation Towards Understanding Breast Cancer Cell Bone Metastasis
William Weidong Du,Ling Fang,Weining Yang,Wang Sheng,Yaou Zhang,Arun Seth,Burton B Yang,Albert J Yee
DOI: https://doi.org/10.1186/1471-2407-12-341
IF: 4.638
2012-01-01
BMC Cancer
Abstract:BACKGROUND:Versican is detected in the interstitial tissues at the invasive margins of breast carcinoma, is predictive of relapse, and negatively impacts overall survival rates. The versican G3 domain is important in breast cancer cell growth, migration and bone metastasis. However, mechanistic studies evaluating versican G3 enhanced breast cancer bone metastasis are limited.METHODS:A versican G3 construct was exogenously expressed in the 66c14 and the MC3T3-E1 cell line. Cells were observed through light microscopy and viability analyzed by Coulter Counter or determined with colorimetric proliferation assays. The Annexin V-FITC apoptosis detection kit was used to detect apoptotic activity. Modified Chemotactic Boyden chamber migration invasion assays were applied to observe tumor migration and invasion to bone stromal cells and MC3T3-E1 cells. Alkaline phosphatase (ALP) staining and ALP ELISA assays were performed to observe ALP activity in MC3T3-E1 cells.RESULTS:In the four mouse breast cancer cell lines 67NR, 66c14, 4T07, and 4T1, 4T1 cells expressed higher levels of versican, and showed higher migration and invasion ability to MC3T3-E1 cells and primary bone stromal cells. 4T1 conditioned medium (CM) inhibited MC3T3-E1 cell growth, and even lead to apoptosis. Only 4T1 CM prevented MC3T3-E1 cell differentiation, noted by inhibition of alkaline phosphatase (ALP) activity. We exogenously expressed a versican G3 construct in a cell line that expresses low versican levels (66c14), and observed that the G3-expressing 66c14 cells showed enhanced cell migration and invasion to bone stromal and MC3T3-E1 cells. This observation was prevented by selective EGFR inhibitor AG1478, selective MEK inhibitor PD 98059, and selective AKT inhibitor Triciribine, but not by selective JNK inhibitor SP 600125. Versican G3 enhanced breast cancer cell invasion to bone stromal cells or osteoblast cells appears to occur through enhancing EGFR/ERK or AKT signaling. G3 expressing MC3T3-E1 cells showed inhibited cell growth and cell differentiation when cultured with TGF-β1 (1 ng/ml), and expressed enhanced cell apoptosis when cultured with TNF-α (2 ng/ml). Enhanced EGFR/JNK signaling appears to be responsible for G3 enhanced osteoblast apoptosis and inhibited osteoblast differentiation. Whereas repressed expression of GSK-3β (S9P) contributes to G3 inhibited osteoblast growth. Versican G3 functionality was dependent on its EGF-like motifs. Without the structure of EGF-like repeats, the G3 domain would not confer enhancement of tumor cell migration and invasion to bone with concordant inhibition of osteoblast differentiation and promotion of osteoblast apoptosis.CONCLUSIONS:Versican enhances breast cancer bone metastasis not only through enhancing tumor cell mobility, invasion, and survival in bone tissues, but also by inhibiting pre-osteoblast cell growth, differentiation, which supply favorable microenvironments for tumor metastasis.
-
Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells
Maziar Rahmani,Jason T Read,Jon M Carthy,Paul C McDonald,Brian W Wong,Mitra Esfandiarei,Xiaoning Si,Zongshu Luo,Honglin Luo,Paul S Rennie,Bruce M McManus
DOI: https://doi.org/10.1074/jbc.M411766200
2005-04-01
Abstract:The proteoglycan versican is pro-atherogenic and central to vascular injury and repair events. We identified the signaling pathways and promoter elements involved in regulation of versican expression in vascular smooth muscle cells. Phosphatidylinositol 3-kinase inhibitor, LY294002, significantly decreased versican-luciferase (Luc) promoter activity and endogenous mRNA levels. We further examined the roles of protein kinase B and glycogen synthase kinase (GSK)-3beta, downstream effectors of phosphatidylinositol 3-kinase, in the regulation of versican transcription. Co-transfection of dominant negative and constitutively active protein kinase B constructs with a versican-Luc construct decreased and increased promoter activity, respectively. Inhibition of GSK-3beta activity by LiCl augmented accumulation of beta-catenin and caused induction of versican-Luc activity as well as versican mRNA levels. Beta-catenin has no DNA binding domain, therefore it cannot directly induce transcription of the versican promoter. Software analysis of the versican promoter revealed two potential binding sites for T-cell factors (TCFs), proteins that confer transcriptional activation of beta-catenin. Electrophoretic mobility shift and supershift assays revealed specific binding of human TCF-4 and beta-catenin to oligonucleotides corresponding to a potential TCF binding site in the versican promoter. In addition to binding assays, we directly assessed the dependence of versican promoter activity on TCF binding sites. Site-directed mutagenesis of the TCF site located -492 bp relative to the transcription start site markedly diminished versican-Luc activity. Co-transfection of TCF-4 with versican-Luc did not increase promoter activity, but addition of beta-catenin and TCF-4 significantly stimulated basal versican promoter activity. Our findings suggest that versican transcription is predominantly mediated by the GSK-3beta pathway via the beta-catenin-TCF transcription factor complex in smooth muscle cells, wherein such regulation contributes to the normal or aberrant formation of provisional matrix in vascular injury and repair events.
-
Versican V1 Isoform Induces Neuronal Differentiation and Promotes Neurite Outgrowth
YJ Wu,W Sheng,LW Chen,HH Dong,V Lee,F Lu,CS Wong,WY Lu,BB Yang
DOI: https://doi.org/10.1091/mbc.e03-09-0667
2004-01-01
Molecular Biology of the Cell
Abstract:The chondroitin sulfate proteoglycan versican is one of the major extracellular components in the developing and adult brain. Here, we show that isoforms of versican play different roles in neuronal differentiation and neurite outgrowth. Expression of versican V1 isoform in PC12 cells induced complete differentiation, whereas expression of V2 induced an aborted differentiation accompanied by apoptosis. V1 promoted neurite outgrowth of hippocampal neurons, but V2 failed to do so. V1 transfection enhanced expression of epidermal growth factor receptor and integrins, and facilitated sustained extracellular signal-regulated kinase/MAPK phosphorylation. Blockade of the epidermal growth factor receptor, beta1 integrin, or Src significantly inhibited neuronal differentiation. Finally, we demonstrated that versican V1 isoform also promoted differentiation of neural stem cells into neurons. Our results have implications for understanding how versican regulates neuronal development, function, and repair.
-
Overexpression of the C-terminal PG-M/versican Domain Impairs Growth of Tumor Cells by Intervening in the Interaction Between Epidermal Growth Factor Receptor and Β1-Integrin
YJ Wu,LW Chen,L Cao,W Sheng,BB Yang
DOI: https://doi.org/10.1242/jcs.01057
IF: 5.235
2004-01-01
Journal of Cell Science
Abstract:Versican is highly expressed in many types of tumors. In a previous study, we found that a G3 mutant [G3DeltaEGF; a versican G3 domain lacking two epidermal growth factor (EGF)-like motifs] exerted a dominant-negative effect on versican secretion and binding. Here, we report that astrocytoma U87 cells expressing the versican G3 mutant lost the hallmark of cell transformation and tumorigenesis in vitro and in vivo. U87 cells expressing G3DeltaEGF had enhanced cell adhesion and spreading, but lost the tumor characteristic of anchorage-independent growth. When U87 cells were deprived of serum, FAK was quickly dephosphorylated, integrin/EGF-receptor (EGFR) complexes dissociated and the cells retained an appropriate level of EGFR phosphorylation. These cells quickly detached, migrated, rounded, reorganized and survived. However, after serum withdrawal from G3DeltaEGF-transfected U87 cells, sustained FAK phosphorylation and integrin-EGFR association were observed, but a greatly reduced EGFR phosphorylation. These cells remained spread and continued to grow before undergoing massive apoptosis. The addition of EGF promoted U87 cell rounding but had little effect on G3DeltaEGF-transfected cells owing to reduced EGFR phosphorylation. Our study sheds light on the question of how the matrix molecule versican modulates tumorigenesis by affecting integrin and EGFR signals.
-
Cleavage of the Carboxyl Tail from the G3 Domain of Aggrecan but Not Versican and Identification of the Amino Acids Involved in the Degradation.
V Lee,LW Chen,F Paiwand,L Cao,YJ Wu,R Inman,ME Adamsi,BB Yang
DOI: https://doi.org/10.1074/jbc.m110227200
2002-01-01
Abstract:Aggrecan, a major structural proteoglycan in cartilage, contains three globular domains, G1, G2, and G3, as well as sequences for glycosaminoglycan modification. A large number of proteases are implicated in aggrecan cleavage in normal metabolism, aging, and arthritis. These proteases are known to cleave at the IGD, KS, and CS domains. Here we report for the first time evidence of cleavage at a novel site, the carboxyl tail of aggrecan. Results from deletion mutants of the tail indicated that the likely cleavage sites were two consensus sequences, RRLXK and RSPR, present in the aggrecan analogs of many species. This was confirmed by site-directed mutagenesis. A construct containing two G3 domains (G3G3) was also found to cleave between the G3 duplicates. When G3 tail was linked to a glycosaminoglycan-modifying sequence, it was protected from cleavage. Furin inhibitor also reduced the levels of tail cleavage. The carboxyl tails of chicken and human versican were not cleaved, despite the presence of the consensus sequence. Our studies indicate that the basic amino acids present in the tail play an important role in cleavage, and this mechanism is specific to aggrecan.
-
The Role of Versican in Modulating Breast Cancer Cell Self-Renewal
William Weidong Du,Ling Fang,Xiangling Yang,Wang Sheng,Bing L. Yang,Arun Seth,Yaou Zhang,Burton B. Yang,Albert J. Yee
DOI: https://doi.org/10.1158/1541-7786.mcr-12-0461
2013-01-01
Molecular Cancer Research
Abstract:Versican is highly expressed during the early stages of tissue development and its expression is elevated duringwound repair and tumor growth. There is little literature on the potential role of breast cancer stem cells on the cellular-extracellular matrix interactions involving versican. An anti-versican short hairpin RNA (shRNA) was used to observe the effect of reduction of versican on breast cancer self-renewal. A versican G3 construct was exogenously expressed in breast cancer cell lines. Colony formation and mammosphere formation assays were conducted; flow cytometry was applied to analyze the prevalence of side population cells. The versican G3- and vector-transfected 66c14 cells were injected transdermally into BALB/c mice as a 10-fold dilution series from 1 x 10(5) to 1 x 10(2) cells per mouse. Versican G3 domain enhanced breast cancer self-renewal in both experimental in vitro and in vivo models. Versican G3-transfected cells contained high levels of side population cells, formed more mammospheres when cultured in the serum-free medium, and formed a greater number and larger colonies. Reduction of versican's functionality through anti-versican shRNA or knocking out the EGF-like motifs reduced the effect of versican on enhancing mammosphere and colony formation. Versican-enhanced self-renewal played a role in enhanced chemotherapeutic drug resistance, relating partly to the upregulated expression of EGF receptor (EGFR) signaling. Versican is highly expressed in breast cancer progenitor cells and was maintained at high levels before cell differentiation. Overexpression of versican enhanced breast cancer self-renewal through EGFR/AKT/GSK-3 beta (S9P) signaling and conferred resistant to chemotherapeutic drugs tested. (C)2013 AACR.
-
Roles of Aggrecan Domains in Biosynthesis, Modification by Glycosaminoglycans and Product Secretion
C Kiani,V Lee,L Cao,LW Chen,YJ Wu,Y Zhang,ME Adams,BB Yang
DOI: https://doi.org/10.1042/0264-6021:3540199
IF: 3.766
2001-01-01
Biochemical Journal
Abstract:Aggrecan is a member of the chondroitin sulphate (CS) proteoglycan family, which also includes versican/PG-M, neurocan and brevican. Members of this family exhibit structural similarity: a G1 domain at the N-terminus and a G3 domain at the C-terminus, with a central sequence for modification by CS chains. A unique feature of aggrecan is the insertion of three additional domains, an inter-globular domain (IGD), a G2 domain and a keratan sulphate (KS) domain (sequence modified by KS chains), between the G1 domain and the CS domain (sequence modified by CS chains). The G1 and G3 domains have been implicated in product secretion, but G2, although structurally similar to the tandem repeats of G1, performs an unknown function. To define the functions of each aggrecan domain in product processing, we cloned and expressed these domains in various combinations in COS-7 cells. The results indicated that the G3 domain enhanced product secretion, alone or in combination with the KS or CS domain, and promoted glycosaminoglycan (GAG) chain attachment. Constructs containing the G1 domain were not secreted. Addition of a CS domain sequence to G1 reduced this inhibition, but GAG chain attachment was still decreased. The potential GAG chain attachment site in the IGD was occupied by GAGs, and IGD product was secreted efficiently. The KS domain was modified by GAG chains and secreted. Finally, the G2 domain was expressed but not secreted, and inhibited secretion of the IGD when expressed as an IGD-G2 combination.
-
The Folded Modules of Aggrecan G3 Domain Exert Two Separable Functions in Glycosaminoglycan Modification and Product Secretion.
LW Chen,YJ Wu,V Lee,C Kiani,ME Adams,YQ Yao,BB Yang
DOI: https://doi.org/10.1074/jbc.m101153200
2002-01-01
Abstract:Aggrecan is the major proteoglycan in the extracellular matrix of cartilage. A notable exception is nanomelic cartilage, which lacks aggrecan in its matrix. The example of nanomelia and other evidence leads us to believe that the G3 domain plays an important role in aggrecan processing, and it has indeed been confirmed that G3 allows glycosaminoglycan (GAG) chain attachment and product secretion. However, it is not clear how G3, which contains at least a carbohydrate recognition domain (CRD) and a complement binding protein (CBP) motif, plays these two functional roles. The present study was designed to dissect the mechanisms of this phenomenon and specially 1) to determine the effects of various cysteine residues in GAG modification and product secretion as well as 2) to investigate which of the two processing events is the critical step in the product processing. Our studies demonstrated that removal of the two amino-terminal cysteines in the CRD motif and the single cysteine in the amino terminus of CBP inhibited secretion of CRD and CBP. Use of the double mutant CRD construct also allowed us to observe a deviation from the usual strict coupling of GAG modification and product secretion steps. The presence of a small chondroitin sulfate fragment overcame the secretion-inhibitory effects once the small chondroitin sulfate fragment was modified by GAG.
-
Distinct effects of different matrix proteoglycans on collagen fibrillogenesis and cell-mediated collagen reorganization
Dongning Chen,Lucas R. Smith,Gauri Khandekar,Pavan Patel,Christopher K. Yu,Kehan Zhang,Christopher S. Chen,Lin Han,Rebecca G. Wells
DOI: https://doi.org/10.1038/s41598-020-76107-0
IF: 4.6
2020-11-04
Scientific Reports
Abstract:Abstract The extracellular matrix (ECM) is a complex mixture composed of fibrillar collagens as well as additional protein and carbohydrate components. Proteoglycans (PGs) contribute to the heterogeneity of the ECM and play an important role in its structure and function. While the small leucine rich proteoglycans (SLRPs), including decorin and lumican, have been studied extensively as mediators of collagen fibrillogenesis and organization, the function of large matrix PGs in collagen matrices is less well known. In this study, we showed that different matrix PGs have distinct roles in regulating collagen behaviors. We found that versican, a large chondroitin sulfate PG, promotes collagen fibrillogenesis in a turbidity assay and upregulates cell-mediated collagen compaction and reorganization, whereas aggrecan, a structurally-similar large PG, has different and often opposing effects on collagen. Compared to versican, decorin and lumican also have distinct functions in regulating collagen behaviors. The different ways in which matrix PGs interact with collagen have important implications for understanding the role of the ECM in diseases such as fibrosis and cancer, and suggest that matrix PGs are potential therapeutic targets.
multidisciplinary sciences
-
Versican Isoforms Modulate Expression and Function of Nicotinic Acetylcholine Receptors.
Yaojiong Wu,Wang Sheng,Haiheng Dong,David Lapierre,Yudi Wan,Wei-Yang Lu,Burton B Yang
2009-01-01
Abstract:Versican is a chondroitin sulfate proteoglycan whose isoforms are differentially expressed, but little is known of their functions in the neuronal system. Here we show that isoforms of versican play different roles in neuronal differentiation and neurite outgrowth. Expression of versican V1 isoform in PC12 cells induced complete neuronal differentiation and increased the expression of nicotinic acetylcholine receptor in NGF-independent manners. The V1-induced neuronal differentiation was different from the NGF-induced differentiation, showing a specific profile of nAChR subunit expression and distinct kinetics of receptor-gated channel activity. Our results have implications for understanding how versican regulates neuronal development, function and repair.